DNA damage repair inhibitors and DNA damage‐inducing agents, including the Poly ADP‐ribose polymerase (PARP)‐inhibitor olaparib and cisplatin, are widely used anticancer drugs with particular benefit to patients with defects in DDR pathways such as BRCA1/2‐positive or ‘BRCAness’ basal breast cancer patients [49, 50]. This evidence concerns the gene BRCA1 and breast cancer.